
Elige tu etiqueta
se ve directamente en el vialSurvodutide
GLP-1
- Envío desde Alemania
Pedido
- DHL con seguimiento
- Embalaje discreto
4.6 de 5 en Trustpilot73 reseñas
También buscado como: Survodutid · BI 456906
De un vistazo
Survodutide en cifras
Las cifras clave de nuestra enciclopedia.
Entrada completa de la enciclopedia- Class
- GLP-1 / glucagon dual agonist
- Half-life
- Several daysweekly dose
- Frequency
- Once weeklysubcutaneous
- Form
- Lyophilised powderreconstituted with BAC water
- Sizes
- 10 mg1 size in the shop
What studies show
All 5 sources in the lexicon- up to~15 %le Roux et al., Lancet Diabetes & Endocrinology, 2024
Phase 2 study in MASH and liver fibrosis (opens in a new tab)
Sanyal et al., New England Journal of Medicine, 2024Phase 3 trial SYNCHRONIZE-1 in obesity without diabetes (725 adults, 76 weeks) (opens in a new tab)
le Roux et al., New England Journal of Medicine, 2026
Todavía no hay ningún análisis de laboratorio de Survodutide. Vota por élHazlo analizar tú mismo, pagamos la mitadTodos los análisis de laboratorio
Conocimiento
Todo sobre Survodutide
Información detallada próximamente.
Dosificación
Cargando información de dosificación …
Conviene tenerlo
Lo que necesitas con ello
El agua bacteriostática se añade automáticamente a tu carrito. Jeringas y toallitas con un clic.
Jeringas de insulina
10 uds. · 5.50 €
Toallitas con alcohol
50 uds. · 10 €
¿Cuánta agua?
Unidades en la jeringa para tu tamaño de vial.
Abrir calculadora →Is Survodutide approved?
No. ChEMBL lists Survodutide with phase 3 as the highest phase. The first phase 3 trials (SYNCHRONIZE-1, SYNCHRONIZE-2 and SYNCHRONIZE-MASLD) are finished and were published in 2026, others are still running. The information here describes the state of research and is not a recommendation for use.
How does Survodutide differ from Semaglutide and Retatrutide?
The receptors. Semaglutide acts only on the GLP-1 receptor, Survodutide also on the glucagon receptor, Retatrutide additionally on GIP. The glucagon part acts mainly in the liver, which is why Survodutide is also tested in fatty liver. In a phase 2 trial in type 2 diabetes the higher levels lowered weight more than semaglutide after 16 weeks.
What did the phase 3 trials show?
In SYNCHRONIZE-1 (without diabetes) weight fell by 12.2 and 13.0 percent after 76 weeks, by 5.4 percent on placebo. In SYNCHRONIZE-2 (with type 2 diabetes) it was 8.2 and 9.8 versus 3.9 percent, HbA1c fell by 0.9 and 0.8 percentage points. In SYNCHRONIZE-MASLD liver fat fell by at least 30 percent in 68.5 percent, on placebo in 28.6 percent.
What is known about the liver?
In a phase 2 trial with biopsy MASH improved without worsening of fibrosis in 43 to 62 percent depending on the dose, in 14 percent on placebo. Fibrosis improved in 34 to 36 versus 22 percent. A study in liver cirrhosis tested uptake and tolerability. Two large phase 3 trials on MASH are still running.
How high were the doses in trials?
The highest study dose was 6 mg per week, in the liver trial and the phase 3 programme. All trials raise the dose in steps over weeks. In the phase 2 trial in overweight the effect rose only a little from the second level on. The entry describes the same principle: start low and only increase until an effect is noticeable. This is not a dosing recommendation.
Which side effects were seen?
Mainly gastrointestinal effects, mostly mild to moderate. In SYNCHRONIZE-1 80.9 and 89.7 percent had them, 47.9 percent on placebo. In the liver trial nausea, diarrhoea and vomiting were clearly more common with Survodutide than with placebo. The trials describe the complaints mainly during escalation.
Which trials are still running?
Three of the listed phase 3 trials are still recruiting: LIVERAGE on MASH with fibrosis (planned end 2031), LIVERAGE-Cirrhosis on MASH with cirrhosis and a trial on blood sugar in type 2 diabetes. The large cardiovascular safety trial with 5,531 participants is finished, results had not been published by October 2026.
Relacionados
Productos relacionados
Tirzepatide
Péptidos · GLP-1 y pérdida de grasa GLP-1 y pérdida de grasa
10 tamaños
Analizado en laboratorio
= desde 10 €/vial
Retatrutide
Péptidos · GLP-1 y pérdida de grasa GLP-1 y pérdida de grasa
11 tamaños
Analizado en laboratorio
= desde 16 €/vial
Semaglutide
Péptidos · GLP-1 y pérdida de grasa GLP-1 y pérdida de grasa
6 tamaños
Analizado en laboratorio
= desde 10 €/vial
Mazdutide
Péptidos · GLP-1 y pérdida de grasa GLP-1 y pérdida de grasa
2 tamaños
= desde 32 €/vial
Survodutide